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Abstract
The presentation reviews the modus operandi of the dose modifying drug Pentoxifylline and the
dose enhancement factors which can be achieved in different cell types. Preclinical and clinical data
show that Pentoxifylline improves the oxygenation of hypoxic tumours and enhances tumour
control by irradiation. In vitro experiments demonstrate that Pentoxifylline also operates when
oxygen is not limiting and produces dose modifying factors in the region of 1.2 – 2.0. This oxygen
independent effect is poorly understood. In p53 mutant cells irradiation induces a G2 block which
is abrogated by Pentoxifylline. The enhancement of cell kill observed when Pentoxifylline and
irradiation are given together could arise from rapid entry of damaged tumour cells into mitosis
and propagation of DNA lesions as the result of curtailment of repair time. Recovery ratios and
repair experiments using CFGE after high dose irradiation demonstrate that Pentoxifylline inhibits
repair directly and that curtailment of repair time is not the explanation. Use of the repair defective
xrs1 and the parental repair competent CHO-K1 cell line shows that Pentoxifylline inhibits
homologous recombination repair which operates predominantly in the G2 phase of the cell cycle.
When irradiated cells residing in G2 phase are exposed to very low doses of cisplatin at a toxic
dose of 5 %. (TC: 0.05) massive toxicity enhancements up to a factor of 80 are observed in
melanoma, squamous carcinoma and prostate tumour cell lines. Enhancements of radiotoxicity
seen when Pentoxifylline and radiation are applied together are small and do not exceed a factor
of 2.0. The capacity of Pentoxifyline to inhibit homologous recombination repair has not as yet been
clinically utilized. A suitable application could be in the treatment of cervical carcinoma where
irradiation and cisplatin are standard modality. In vitro data also strongly suggest that regimes
where irradiation is used in combination with alkylating drugs may also benefit.
Introduction
The methylxanthine drug Pentoxifylline (TRENTAL,
Sanofi-Aventis) is clinically well established for the treat-
ment of cerebral ischemia and a variety of other vasooc-
clusive disorders such as intermittent claudication.
[14,50]. Systemically the drug operates by enhancing the
flexibility of blood cell membranes and reducing blood
viscosity. The positive influence of Pentoxifylline on the
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microcirculation and peripheral oxygenation has led to
applications in experimental radiotherapy showing small
but consistent improvements of the radiotoxicity. Injec-
tion of PFX followed by irradiation 45 minutes later pro-
duces a 1.1–1.5 fold enhancement of tumour growth
delay and this is associated with a marked reduction of
tumour anoxia.[10,23,25-27,41,42,47,52].
Apart from the systemic effects there is now a long list of
published data indicating that Pentoxifylline (and the
related drug caffeine) influences the radiobiological
responses of tumour cells in an oxygen independent man-
ner. Given to tumour cell cultures before irradiation at the
subtoxic dose of 2 mM, Pentoxifylline effectively
enhances radiotoxicity measured by clonogenic cell sur-
vival by factors of 1.2–2.0 [3,4,9,45-47].
In the following I summarize our own [54] and other new
in vitro data which explore the effects of this interesting
drug on the damage responses of tumour cells. It is shown
that Pentoxifylline emerges as an effective repair inhibitor
and that this new mechanistic understanding shows great
promise for application in tumour therapy.
Materials and methods
The determination of the drug toxicity enhancement fac-
tors for Melphalan, Daunorubicin and Cisplatin are based
on chemosensitivity measurements using the crystal violet
assay. G2/M block abrogation and measurment of cell
survival under conditions of G2 block abrogation and
drug addition involved control experiments measuring
cell survival for irradiation alone, Pentoxifylline alone,
Pentoxifylline plus irradiation, Pentoxifylline plus drug at
5 % toxicity and cytostatic drug alone. Data obtained by
addition of Pentoxifylline were normalized with respect
to controls containing Pentoxifylline alone. 12–20 hours
postirradiation when the G2 block assesed by flow cytom-
etry was maximally expressed, Pentoxifylline at 2 mM was
added. The cytostatic drugs Daunorubicin, Melphalan or
Cisplatin were added at a concentration which resulted in
5 % toxicity for drug only controls. These low drug con-
centrations were necessary to ensure detection of the tox-
icity enhancements induced by Pentoxifylline in the
survival and vital dye staining assays. The additions were
made either at the time of maximum G2 block expression
or 7 hours later when the G2 block had been abrogated.
For further experimental detail consult [4].
For cytotoxicity and repair experiments the normal CHO-
K1 hamster cell line and the repair deficient xrs1-mutant
cell line were grown in MEM alpha medium as decribed
[65]. Irradiation and cell survial by clonogenic assay were
as given in [4]. Exposure to 2 mM Pentoxifylline, 1 mM
Caffeine, 15 µ or 20 mM dimethylsulfoxide (DMSO) was
for 40 minutes in medium before irradiation and for 20
hrs after irradiation when the medium was replaced with
drug free medium and incubation continued until forma-
tion of viable colonies. Pentoxifylline toxicity was deter-
mined over a dose range of 0–8 mM, Caffeine 0–4 mM
and Wortmannin 0–25 µM. Wortmannin served as inhib-
itor of non-homolgous endjoining (NHEJ) repair. Repair
assessment by constant field gel electrophoresis (CFGE)
was as previously described [45,66]. Confluent cultures
were used to minimize S-phase variation. Encapsulation
of cells in agarose plugs was as given previously [45,66] to
avoid non-specific DNA damage. Cells harvested by
trypsinisation were resuspended in a 0.5 % low melting
point agarose solution and aliquots of 30 µl, containing
~0.5 × 105 cells, were placed into each well of a disposable
plug mold (BioRad), and allowed to solidify at 4°C for 45
min. Plugs were irradiated in ice-cold MEM containing 2
% HEPES, over a dose range of 0–100 Gy at dose rate of
2.78 Gy/min. The residual damage was determined by
incubating plugs at 37°C in growth medium for periods
of 2–20 hours. For repair in the presence of Pentoxifylline
or Caffeine the cells were irradiated with 60Co γ -irradia-
tion in ice-cold MEM containing 2 % HEPES and 2 mM
Pentoxifylline, or 1 mM Caffeine over a dose range of 0–
100 Gy on ice. After irradiation the plugs were transferred
to preheated (37°C) MEM alpha medium containing the
same drug concentrations and incubated for 2 and 20
hours to allow for repair.
For both protocols (initial and residual damage), plugs
were submersed in an ice-cold lysing solution containing
50 mM EDTA, 1 % N-lauryl-sarcosine and 1 mg/ml Pro-
teinase K. Incubation of 1 hour at 4°C was followed by
lysing at 37°C for 20 hours. Agarose plugs were then
washed five times (50 mM EDTA) and stored in 2 ml of 50
mM EDTA solution. Agarose plugs were loaded into a 20
× 20 cm 0.6 % agarose gel and run in 0.5 × TBE buffer for
30 hours at a constant field strength of 1.2 V/cm. Gels
were stained with ethidium bromide (0.5 µg/ml in 0.5 ×
TBE) and subjected to fluorometric analysis with a Gene-
Snap (VacuTec) image analysis system. The fraction of
DNA released from the plug was obtained from the fol-
lowing equation:
where flrel and flplug correspond to fluorescence measured
in the lane with high mobility DNA and non-mobile DNA
in the control plug respectively. Untreated control sam-
ples were used for each sample subset to subtract back-
ground fluorescence caused by non-specific DNA
degradation. Dose response curves were obtained by plot-
ting dose (Gy) vs. the fraction of DNA released (Frel) as cal-
culated above, representing initial damage (0 hours),
residual damage (2 hours) and residual damage (20
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hours). Since data could not be fitted by linear regression,
data points were connected and the area under the curve
(AUC) was calculated for each curve in the GraphPad
Prism (GraphPad software, San Diago, USA) computer
program.
Results and discussion
Enhancement of radiotoxicity is tumour cell specific
The capacity of Pentoxifylline to enhance cytotoxicity was
first noted in T24 bladder tumour cells treated with the
alkylating agent Thiotepa showing a 3 fold reduction of
cell survival and stimulation of mitotic progression [17].
Using Cobalt 60 irradiation as the intervention and SF2 as
the reference point we demonstrated that 2 mM Pentoxi-
fylline enhances the radiotoxicity by a factor of 1.10 in
V79 cells and by a factor of 1.60 in Hela cells [47]. The
radiotoxicity enhancement factors are cell line and irradi-
ation dose dependent and range from 1.2 to 2.0 at 2 Gy
reaching 3–14 at 10 Gy in human melanoma, squamous
cell carcinoma and in murine cell lines [4,5,45]. Caffeine
at 1 mM has been found to enhance radiotoxicity by mar-
gins of 1.4 – 4.6 in US9-93 and by 1.4–2.0 in LMS6-93
human sarcoma lines [2]. 1 mM caffeine and 2 mM Pen-
toxifylline alone are not cytotoxic in most cell lines [4,7].
A trend first noted in A 549 p53 transfectants was the
observation that radiosensitisation by methylxanthines
operates more effectively in p53 mutant than in p 53 wild
type cells [22,39]. This has since been corroborated in a
wide range of p53 wild type and p53 mutant pairs of cell
lines [2,4,5,40]. The sensitizing influence of Pentoxifyl-
line and Caffeine is not restricted to irradiation but also
applies to cytotoxic drugs [2,17,22,29].and to UV-irradia-
tion [11,31].
Abrogation of G2 blocks and indications for a role of repair
Evidence for a role of Pentoxifylline and caffeine in repair
comes from the observation that p53 mutant and p53
defective cells in general are preferentially sensitized to
irradiation whereas p53 wild type cells show no or only a
mild sensitisation response [15,38,47]. These circum-
stances would offer a mechanism for selective targeting of
tumour cells [15,19,22,39]. In this mechanism irradiated
cells blocked in G2 phase would progress prematurely
into mitosis and G1 phase and thus be subjected to a
shortened repair time [28,37,39]. We have shown that the
abrogating effect involves early restoration of cyclin B1
and p34 cdc-2 levels in the mitosis promoting factor to
pre-irradiation levels [43,44] and also gives rise to a 3–5
fold increase of Histone H3 phosphorylation [3] which is
diagnostic of mitotic progression [18]. When we induced
the G2 M block with the spindle inhibitor Nocodazole,
Pentoxifylline was ineffective in abrogating G2 blocks,
leaving G2 populations in p53 mutants at the level of 80
% for 10 hrs after drug addition whereas presence of Pen-
toxifylline for 7 hours in irradiated cells would reduce the
G 2 population from 60 to 19 % [7]. This demonstrates
that Pentoxifylline does not operate at the spindle assem-
bly checkpoint [7]. A popular explanantion for the
enhanced radiotoxicity generated by Pentoxifylline has
been that early transit of cells into mitosis would shorten
repair time [11,15,30,37-39]. But this view may be sim-
plistic and has been questioned by us [5,45] and by other
investigators [19,35]. We have shown that addition of
Pentoxifylline 12 hours postirradiation when the G2
block is maximally expressed and repair is essentially
complete does not produce any radiosensitization [5,45].
The lack of a correlation between G2 block abrogation
and cytotoxicity enhancement also argues against a role of
reduced repair time [36]. It therefore seems that prema-
ture entry of G2 blocked cells into mitosis is not the criti-
cal event which can explain radiosensitization [5,45].
Nevertheless the conclusion that Pentoxifylline sup-
presses DNA repair is not without substance as shown by
delayed plating experiments indicating inhibition of
potential lethal damage repair [31]. Presence of 2 mM
Caffeine in irradiated preimplantation chick embryo blas-
tomeres and analysis by comet assay has shown that the
restoration of DNA damage is inhibited in the early 2
hour time frame [33]. Further evidence for a role of early
repair events comes from our laboratory showing that
Pentoxifylline reduces the recovery ratios in 3 hour split
dose experiments from 3.0 ± 0.40 to 1.0 ± 0.18 in irradi-
ated Hela cells [47].
New evidence supporting a role of Pentoxifylline in repair 
inhibition
The requirement of methylxanthine presence at the time
of irradiation for any sizable radiosensitization to occur
[4,45] and delayed plating experiments [35] strongly sug-
gest that early damage responses are influenced. When we
evaluated DNA repair by CFGE and assessed mobile DNA
fragments after high dose exposure we found unequivocal
evidence that Pentoxifylline effectively suppresses DNA
double strand break repair in p53 mutant human
melanoma and squamous cell carcinoma lines [45] and
various p53 transfectants [5]. Further significant progress
in the understanding of the mechanism of action of caf-
feine in radiosensitization has come from experiments
using repair deficient mutants. It was observed that a rad
51 paralogue XRCC2 irs1 line defective in homologous
recombination (HR) shows significantly diminished caf-
feine radiosensitization which can be restored by expres-
sion of XRCC2 [1]. Consistent with these results is the
finding that an irs-20 cell line mutant for DNA-PK and
defective in non-homologous endjoining (NHEJ) is radi-
osensitized by caffeine to an extent comparable with
wildtype cells [49]. These observations have been con-
firmed in other rad 51 mutants and in ATM -/- cells
strongly suggesting that caffeine selectively targets steps in
DNA double strand break repair which require HR [48].Radiation Oncology 2006, 1:12 http://www.ro-journal.com/content/1/1/12
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Strong evidence for a role of Pentoxifylline in HR is pre-
sented in CFGE repair assays using the parental CHO-K1
cells and the NHEJ defective xrs-1 mutant. In CHO-K1
wildtype cells operating both repair pathways we found
Wortmannin to strongly enhance radiotoxicity and sup-
press survival whereas the xrs-1 mutant that is defective in
NHEJ repair showed no change of cell survival. CFGE
repair data after high doses of irradiation furthermore
indicated Wortmannin to inhibit repair only in the CHO-
K1 wildtype cells confirming that the cell pair is a repre-
sentative model for addressing the question of HR repair
(Roos & Bohm, unpublished). Testing of Pentoxifylline in
this system and analysis of mobile unrepaired DNA frag-
ments shows that repair is most strongly inhibited in the
xrs-1 cell line which essentially operates HR-repair only,
but less strongly in the parental fully repair competent
CHO-K1 cell line which also operates NHEJ repair (Figure
1). These results are in excellent agreement with data on
NHEJ deficient 180BRM and XR-1 cells where caffeine
induced depression of survival was found to be much
greater than in the parental NHEJ proficient MRC5SV1
and CHO cell lines [49] suggesting that caffeine induced
radiosensitisation is caused by an NEHJ independent
process [48]. Experiments in A 549 lung adenocarcinoma
and in K562 erythroblastoid leukaemia cells have shown
that caffeine inhibits ATM and ATR kinases which control
checkpoints via phosphorylation of p53 thereby main-
taining the G2 block and controlling HR repair
[21,24,32,48,51]. The close structural and functional rela-
tionship between Caffeine and Pentoxifylline strongly
suggests that ATM inhibition also applies to Pentoxifyl-
line.
Another indication that HR repair processes are extremely
sensitive to Pentoxifylline is shown in experiments in
which p53 mutant cells blocked in G2 by irradiation were
exposed to a second cytotoxin at a dose which would
induce 95 % survival or 5 % cell kill (TD05) in fully
cycling cells in the absence of Pentoxifylline. Addition of
such low concentrations of common cytotoxins to G2
blocked cells in the presence of Pentoxifylline generates
very large enhancements of drug toxicity in the range of
2.3–2.8; 8.6–85 and 52–74 for Vinblastine, Melphalan
and cisplatin respectively (Table 1). In similar experi-
ments in p53 wildtype LNCaP and p53 mutant DU-145
and BM 12604 prostate cells we found dose enhancement
factors of 1.5–4.5 for the p53 mutant cells and 1.4–1.6 for
the p53 wildtype LNCaP cells Table 1 and [40]. The
extreme sensitivity of repair events in G2 is evident by the
fact that up to 85 fold toxicity enhancement is achieved at
Constant field gel electrophoresis (CFGE) repair assay showing influence of Pentoxifylline on fractions of DNA released in  response to irradiation dose for the parental CHO-K1 cells and NHEJ-defective xrs1 mutant cell line Figure 1
Constant field gel electrophoresis (CFGE) repair assay showing influence of Pentoxifylline on fractions of DNA released in 
response to irradiation dose for the parental CHO-K1 cells and NHEJ-defective xrs1 mutant cell line. Adapted from [6].Radiation Oncology 2006, 1:12 http://www.ro-journal.com/content/1/1/12
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drug doses which are 1–3 orders of magnitude lower than
standard therapeutic doses (Table 1). The wide variation
of the dose enhancement between cell types and cytotoxic
drugs would support a model in which repairability of the
lesion plays a role.
Clinical ramifications
The clinical merits of Pentoxifylline on tumour control
and survival when combined with irradiation cannot as
yet be judged with any finality. For stage I, II, and III non-
small cell lung cancer giving 3 × 400 mg Pentoxifylline/
day with conventional dose fractionation the complete
and partial responses were similar but the median time to
relapse was 2 month longer in the Pentoxifylline group
than in controls. In the Pentoxifylline group the median
survival was 18 month as compared to 7 month in the
control group. The differences in 1-year and 2-year sur-
vival found to be 60 % as compared to 35 % and at 18 %
as compared to 12 % respectively but were not statistically
significant. This stage III randomised multicenter trial
concluded that Pentoxifylline is a modestly effective radi-
ation response modifier [57]. In a phase II evaluation on
brain metastases in 14 patients the median survival time
was 33 days and identical to historical controls showing
no drug toxicity and supporting higher doses for future tri-
als [58]. In another phase II single center trial on 11
patients with glioblastoma multiforme evaluating the
influence of Pentoxifylline on utilization and effective-
ness of cytotoxic drugs the median survival for all patients
was 26 weeks from initial diagnosis showing no obvious
benefits [59]. In a rhabdomyosarcoma rat model giving
50 mg Pentoxifylline/kg before irradiation we demon-
strated a marked improvement of tumour oxygenation
and dose enhancement factors of 1.10 for conventional
dose fractionation and 1.37 for continuous hyperfraction-
ated irradiation, the higher value perhaps arising from
lower vascular injuries [52]. In the light of these data and
the well-documented effectiveness of Pentoxifylline on
the microcirculation it is surprising that the improve-
ments to radiation toxicity and tumour control have
remained small.
An area that now attracts great clinical interest is the abil-
ity of Pentoxifylline to ameliorate late radiation injury.
Pentoxifylline inhibits the hypoxia induced upregulation
of Tissue Factor (TF) a procoagulant stimulus known to
upregulate VEGF and angiogenesis [60]. Pentoxifylline is
also an effective phosphodiesterase inhibitor showing
anti-inflammatory and immunosuppressive effects due to
suppression of TNF-α and inhibition of IL-1 and IL-2
induced lymphocyte stimulation [reviewed in [52]]. In
view of this broad spectrum of activities and down regula-
tion of cytokines it is not surprising that Pentoxifylline
inhibits effects that are stimulated by radiation and tissue
injury. In patients receiving radiotherapy for sqamous car-
cinoma of the head and neck Pentoxifylline given concur-
rently with irradiation has been found to suppress skin
fibrosis and soft tissue necrosis [61]. Given post fac-
tumwhen late tissue damage from irradiation was already
manifest a combination of Pentoxifylline and the antioxi-
dant  α -Tocopherol has been found to be effective in
reducing grade I-II radiation proctitis/enteritis [62] and in
the regression of superficial radiation induced fibrosis
[63].
A recent clinically motivated study on T 98 G human gli-
oma cells has demonstrated that application of Pentoxi-
fylline before 3 intermittent irradiation doses of 4 Gy
consistently sensitised cells by a factor of 4 as compared to
a single dose of 12 Gy in the presence of Pentoxifylline
[13]. This suggests a role for Pentoxifylline in repair inhi-
bition between dose fractions and possible application in
stereotactic surgery [13]. Another clinically realistic sce-
nario emerges from the toxicity enhancements observed
when irradiated tumour cells which have entered the G2
cell cycle block are subjected to cisplatin (Table 1). Irradi-
ation and cisplatin are accepted modalities in the treat-
ment of cervical cancer where low doses of cisplatin are
Table 1: Drug toxicity enhancement factors (EF's) obtained in human tumour cell lines when cells were blocked in G2 with irradiation 
and then subjected to Pentoxifylline and a TC: 05 dose of a cytotoxic drug. Data adapted from [6]
Cell line a Drug EF's
4197 p53 wt b D, M, CP 1.3 3.0 2.6
4451 p53 mut b D, M, CP 2.3 8.6 52
Be11 p53 wtb D, M, CP 1.4 2.3 1.2
MeWo p53 mut b D, M, CP 2.8 85 74
DU 145 p53 mut c V, E, CP 4.8 1.5 4.1
BM1604 p53 mut c V, E, CP 2.6 1.0 4.5
LNCaP p53 wt c V, E, CP 1.4 1.5 1.6
a) 4197 and 4451 are human squamous carcinoma cell lines. Be-11 and MeWo are human melanoma cell lines. The DU-145 prostatic tumour cell 
line was established from a metastatic central nervous system lesion. The BM 1604 cell was established from a radical prostatectomy biopsy. The 
LnCaP cell line was established from a supraclavicular lymph node metatstasis of a human prostate adenocarcinoma.
D: Daunorubicin; E: Etoposide; M: Melphalan; V: Vinblastine; CP: cisplatin based on clonogenic SF 7 (survival fraction at 7 Gy) and dye staining data 
b) Binder et al. [4] ; c) Serafin et al. [40]Radiation Oncology 2006, 1:12 http://www.ro-journal.com/content/1/1/12
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given as a radiosensitizer. In this case cisplatin operates by
mildly inhibiting NHEJ repair of irradiation induced dou-
ble strand breaks [55,56]. In view of the very high in vitro
toxicity enhancement factors measured in melanoma and
squamous carcinoma lines (Table 1) and assuming a p53
mutant status of the tumour, introduction of Pentoxifyl-
line and cisplatin to tumour cells blocked in G2 by irradi-
ation, could markedly improve the therapeutic outcome.
The approach has been recommended for clinical trials by
an international panel assembled by the IAEA [53]. With
the addition of Pentoxifylline and cisplatin to irradiated
tumours it may indeed be possible to harness a very sub-
stantial cisplatin toxicity which is not seen when cisplatin
is given as a radiosensitizer in the absence of Pentoxifyl-
line. Another candidate for the combination of Pentoxi-
fylline with a cytotoxic drug would be melphalan which
shows an even higher (85 fold) increase of toxicity in G2
cells when homologous recombination is inhibited. It is
interesting to note that the two drugs showing the highest
toxicity enhancements, i.e. Cisplatin and Melphalan
when given alone produce a lethal double strand lesion
only after replication [20]. In the scenario suggested here
the drugs would be given after irradiation when the target
is already compromised by double strand breaks. Presence
of the HR inhibitor and stimulation of mitotic progres-
sion may constitute a very adverse environment for
genomic restitution to proceed. While the benefits of Pen-
toxifylline on tumour control when given postirradiation
remain to be clinically verified very recent observations on
BRCA2 deficient cells have indicated that persistence of
DNA lesions (in this case arising postreplication from the
inhibition Poly (ADP-ribose) polymerase) and a defunct
HR pathway are attractive strategies for new and less toxic
therapies of cancer [8,16]. I suggest that p53 mutant and
p53 dysfunctional tumour cells could be effective targets
for cytostatic intervention and repair inhibition in con-
junction with radiotherapy.
Conclusion
The influence of Pentoxifylline on the microcirculation
and peripheral oxygenation has generated a long-standing
and enthusiastic interest in applying this drug for the
treatment of cancer by irradiation. While improved
tumour oxygenation has been documented, the clinical
benefit of Pentoxifylline when given in conjunction with
irradiation to achieve better tumour control and patient
survival has been modest if not disappointing. There is
now a resurge of interest in this drug for controlling late
radiation morbidity. This application is based upon the
ability of Pentoxifylline to suppress lymphocyte activa-
tion and cytokine mediated inflammatory and fibrotic
processes. At present the successes in this area seem to be
more encouraging than in the former.
A large body of in vitro data has shown that Pentoxifylline
given in conjunction with irradiation exerts an oxygen
independent effect on tumour cells by enhancing the radi-
otoxicity by factors of 1.2 – 2.0. The simplistic and widely
accepted interpretation of this effect is that the drug abro-
gates the G2 block and promotes early mitosis thereby
propagating DNA lesions. It is shown here that G2 block
abrogation is not the explanation and that damage
responses rather than the initial DNA lesion are affected.
Pentoxifylline directly inhibits homologous recombina-
tion repair. We find tumour cells residing in G2 phase
when challenged with a cytotoxic drug and Pentoxifylline
to undergo an up to 80 fold enhancement of drug toxicity.
This is in line with the compromised repair options of G2
cells. This ability of Pentoxifylline to markedly enhance
drug toxicity has not yet been clinically utilized but shows
considerable promise in radiotherapy. A suitable applica-
tion would be in the treatment of cervical cancer where
irradiation and cisplatin are standard modality.
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